Септический артрит у взрослых

Ольга Вячеславовна Теплякова; Владимир Александрович Руднов; Г.И.  Шлыкова; Т.Г.  Доценко

Септический артрит у взрослых

Клиническая Микробиология и Антимикробная Химиотерапия. 2015; 17(3):187-206

Теплякова О.В., Руднов В.А., Шлыкова Г.И., Доценко Т.Г.

септический артрит диагностика артрит протезированных суставов антибиотикотерапия антибиотикопрофилактика

Раздел

Болезни и возбудители

Тип

Журнальная статья

Публикация

Клиническая Микробиология и Антимикробная Химиотерапия. 2015; 17(3):187-206

Аннотация Авторы Литература PDF Статистика Репринты

Аннотация

Септический артрит является неотложной клинической ситуацией: деструктивные изменения в суставе происходят быстро и приводят к значительной функциональной недостаточности и смерти. Риск септических артритов существенно возрастает у пациентов с преморбидными поражениями суставов (особенно ревматоидным артритом), а также после эндопротезирования суставов. Постановка точного диагноза затруднена и часто отсрочена, особенно у пациентов с сопутствующими воспалительными заболеваниями суставов. В обзоре приведены данные по эпидемиологии, факторам риска, алгоритмам диагностики септического артрита, выделены ведущие возбудители заболевания в зависимости от клинических групп и географических регионов, рассмотрены проблемы оптимальной эмпирической антибиотикотерапии и обсуждены вопросы антибиотикопрофилактики септического артрита у взрослых.

Теплякова Ольга Вячеславовна

oteplyakova@e1.ru

Уральский государственный медицинский университет, Екатеринбург, Россия
МО «Новая больница», Екатеринбург, Россия

Руднов Владимир Александрович

0000-0003-0830-786X

Шлыкова Г.И.

МО «Новая больница», Екатеринбург, Россия

Доценко Т.Г.

МО «Новая больница», Екатеринбург, Россия

1. Gupta M.N., Sturrock R.D., Field M.A. Рrospective 2-year study of 75 patients with adult-onset septic arthritis. Rheumatology 2001; 40:24-30.
2. Weston V.C., Jones A.C., Bradbury N., et al. Clinical features and outcome of septic arthritis in a single UK Health District 1982-1991. Ann Rheum Dis 1999; 58:214-19.
3. Geirsson A.J., Statkevicius S., Vı´kingsson A. Septic arthritis in Iceland 1990-2002: increasing incidence due to iatrogenic infections Ann Rheum Dis 2008; 67:638-43.
4. Kaandorp J.E., Dinant J., van de Laar A.F.J., et al. Incidence and sources of native and prosthetic joint infection: a community based prospective survey. Anne Rheum Dis 1997; 56:470-75
5. Kellgren J.H., Ball J., Fairbrother R.W., Barnes K.L. Suppurative arthritis complicating rheumatoid arthritis. Br Med J 1958; 1(5081):1193-200.
6. Galloway J.B., Hyrich K.L., Mercer L.K., et al. Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011; 70:1810-4.
7. Favero M., Schiavon F., Riato L., et.al. Rheumatoid arthritis is the major risk factor for septic arthritis in rheumatological settings. Autoimmun Rev 2008; 8(1):59-61.
8. Doran M.F., Crowson C.S., Pond G.R., et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002; 46:2287-93.
9. Edwards C.J., Cooper C., Fisher D., et al. The importance of the disease process and disease-modifying antirheumatic drug treatment in the development of septic arthritis in patients with rheumatoid arthritis. Arthritis Rheum. 2007; 57:1151-7.
10. Dolganiuc A., Stavaru C., Anghel M., et al. The migratory and phagocytic activity of polymorphonuclear leukocytes in rheumatoid arthritis and osteoarthritis patients. Roum Arch Microbiol Immunol 2000; 59(1-2):43-53.
11. Mahowald M.L. Animal models of infectious arthritis. Clin Rheum Dis 1986; 12(2):403-21.
12. Wilton J.M., Gibson T., Chuck C.M. Defective phagocytosis by synovial fluid and blood polymorphonuclear leucocytes in patients with rheumatoid arthritis. Rheumatol Rehabil 1978; Suppl:25-36.
13. Nolla J.M., Gómez-Vaquero C., Fiter J., et al. Pyarthrosis in patients with rheumatoid arthritis: a detailed analysis of 10 cases and literature review. Semin Arthritis Rheum 2000; 30(2):121-6.
14. Dubost J.J., Fis I., Soubrier M., Lopitaux R., et al. Septic arthritis in rheumatoid polyarthritis. 24 cases and review of the literature Rev Rhum Ed Fr 1994; 61(3):153-65.
15. Yu K.H., Luo S.F., Liou L.B., et al. Concomitant septic and gouty arthritis-an analysis of 30 cases. Rheumatology 2003; 42:1062-6.
16. Kaandorp C.J., Krijnen P., Moens H.J., et al. The outcome of bacterial arthritis: a prospective community-based study. Arthritis Rheum 1997; 40(5):884-92.
17. Zimmerli W., Trampuz A., Ochsner P.E. Prosthetic-Joint Infections N Engl J Med 2004; 351:1645-54.
18. European Centre for Disease Prevention and Control. Sexually transmitted infections in Europe, 1990-2009. Stockholm: ECDC; 2011.
19. Kerle K.K., Mascola J.R., Miller T.A. Disseminated gonococcal infection. Am Fam Physician 1992; 45(1):209-14.
20. Takahashi S., Takeyama K., Kunishima Y., et al. Incidence of sexually transmitted diseases in Hokkaido, Japan, 1998 to 2001. J Infect Chemother 2004; 10:163-7.
21. Belkacem A., Caumes E., Ouanich J., et al. Working Group FRA-DGI. Changing patterns of disseminated gonococcal infection in France: cross-sectional data 2009- 2011. Sex Transm Infect 2013; 89(8):613-5.
22. Dubost J.J., Fis I., Denis P., et al. Polyarticular septic arthritis. Medicine 1993; 72(5):296-310.
23. Gardner G.C., Weisman M.H. Pyarthrosis in patients with rheumatoid arthritis: a report of 13 cases and a review of the literature from the past 40 years Am J Med 1990; 88:503-11.
24. Mateo Soria L., Miquel Nolla Solé J., Rozadilla Sacanell A., et al. Infectious arthritis in patients with rheumatoid arthritis. Ann Rheum Dis 1992; 51(3):402-3.
25. Gordon Rachel J., Lowy Franklin D. bacterial infections in drug users. N Engl J Med 2005; 353:1945-54.
26. Brancos M.A., Peris P., Miro J.M., et al. Septic arthritis in heroin addicts. Semin Arthritis Rheum 1991; 21:81-7.
27. Allison D.C., Holtom P.D., Patzakis M.J., Zalavras C.G. Microbiology of bone and joint infections in injecting drug abusers. Clin Orthop Relat Res 2010; 468(8):2107- 12.
28. Al-Nammari S.S., Bobak P., Venkatesh R. Methicillinresistant Staphylococcus aureus versus methicillin sensitive Staphylococcus aureus adult haematogenous septic arthritis. Arch Orthop Trauma Surg 2007; 127(7):537-42.
29. Frazee B.W., Fee C., Lambert L. How common is MRSA in adult septic arthritis? Ann Emerg Med 2009; 54(5):695-700.
30. Ross J.J., Davidson L. Methicillin-resistant Staphylococcus aureus septic arthritis: an emerging clinical syndrome. Rheumatology 2005; 44:1197-8.
31. Fangtham M., Baer A.N. Methicillin-resistant Staphylococcus aureus arthritis in adults: case report and review of the literature. Semin Arthritis Rheum 2012; 41(4):604-10.
32. O’Brien J.P., Goldenberg D.L., Rice P.A. Disseminated gonococcal infection: a prospective analysis of 49 patients and a review of pathophysiology and immune mechanisms. Medicine 1983; 62:395-406.
33. Gristina A.G. Biomaterial-centered infection: microbial adhesion versus tissue integration. Science 1987; 237:1588-95.
34. Carpenter C.R., Schuur J.D., Everett W.W., Pines J.M. Evidence-based diagnostics: adult septic arthritis. Acad Emerg Med 2011; 18(8):781-96.
35. Stumpe K.D., Strobel K. Osteomyelitis and arthritis. Semin Nucl Med 2009; 39(1):27-35.
36. Margaretten M.E., Kohlwes J., Moore D., Bent S. Does this adult patient have septic arthritis? JAMA 2007; 297:1478-88.
37. Yi P.H., Cross M.B., Moric M., et al. The 2013 Frank Stinchfield Award: Diagnosis of infection in the early postoperative period after total hip arthroplasty Clin Orthop Relat Res 2014; 472(2):424-9.
38. Coutlakis P.J., Roberts W.N., Wise C.M. Another look at synovial fluid leukocytosis and infection. J Clin Rheumatol 2002; 8(2):67-71.
39. Trampuz A., Hanssen A.D., Osmon D.R. et al. Synovial fluid leukocyte count and differential for the diagnosis of prosthetic knee infection. Am J Med 2004; 117:556- 62.
40. Ghanem E., Parvizi J., Burnett R.S. Cell count and differential of aspirated fluid in the diagnosis of infection at the site of total knee arthroplasty. J Bone Joint Surg Am 2008; 90:1637-43.
41. Della Valle C.J., Sporer S, M,, Jacobs J, J. Preoperative testing for sepsis before revision total knee arthroplasty. J Arthroplasty 2007; 22(Suppl 2):90-3.
42. Schinsky M.F., Della Valle C.J., Sporer S.M. Perioperative testing for joint infection in patients undergoing revision total hip arthroplasty. J Bone Joint Surg Am 2008; 90:1869-75.
43. Hügle T., Schuetz P., Mueller B. Serum procalcitonin for discrimination between septic and non-septic arthritis. Clin Exp Rheumatol 2008; 26(3):453-6.
44. Fottner A., Birkenmaier C., von Schulze Pellengahr C., et al. Can serum procalcitonin help to differentiate between septic and nonseptic arthritis? Arthroscopy. 2008; 24(2):229-33.
45. Wahong D., Liao Q., Liao Q., et al. Procalcitonin levels in fresh serum and fresh synovial fluid for the differential diagnosis of knee septic arthritis from rheumatoid arthritis, osteoarthritis and gouty arthritis. Exp and Ther Med 2014; 8:1075-80.
46. Hindle Р., Davidson Е., Biant L.C. Septic arthritis of the knee: the use and effect of antibiotics prior to diagnostic aspiration Ann R Coll Surg Engl 2012; 94:351-5.
47. Atkins B.L., Athanasou N., Deeks J.J., et al. Prospective evaluation of criteria for microbiological diagnosis of prosthetic-joint infection at revision Arthroplasty J Clin Microbiol 1998; 36:2932-9.
48. Jalava J., Skurnik M., Toivanen A., et al. Bacterial PCR in the diagnosis of joint infection. Ann Rheum Dis 2001; 60:287-9.
49. Tarkin I.S., Henry T.J., Fey P.I., et al. PCR rapidly detects methicillin-resistant staphylococci periprosthetic infection. Clin Orthop Relat Res 2003:89-94.
50. Nijhof M.W., Oyen W.J., van Kampen A., et al. Evaluation of infections of the locomotor system with indium-111-labeled human IgG scintigraphy. J Nucl Med 1997; 38:1300-5.
51. Karchevsky M., Schweitzer M.E., Morrison W.B., Parellada J.A. MRI findings of septic arthritis and associated osteomyelitis in adults. Am J Roentgenol 2004; 182:119-22.
52. Tigges S., Stiles R.G., Roberson J.R. Appearance of septic hip prostheses on plain radiographs. AJR Am J Roentgenol 1994; 163:377-80.
53. Nagoya S., Kaya M., Sasaki M., et al Diagnosis of periprosthetic infection at the hip using triple-phase bone scintigraphy. J Bone Joint Surg Br 2008; 90:140-4.
54. Newman J.H. Review of septic arthritis throughout the antibiotic era. Ann Rheum Dis 1976; 35:198-205.
55. Coakley G., Mathews C., Field M., et al.; British Society for Rheumatology Standards, Guidelines and Audit Working Group. BSR & BHPR, BOA, RCGP and BSAC guidelines for management of the hot swollen joint in adults Rheumatology 2006; 45(8):1039-41.
56. Parvizi J., Zmistowski B., Berbari E.F., et al New definition for periprosthetic joint infection: from the Workgroup of the Musculoskeletal Infection Society. Clin Orthop Relat Res 2011; 469:2992-4.
57. Blackburn W.D., Dunn T.L., Alarcon G.S. Infection versus disease activity in rheumatoid arthritis: eight years’ experience. South Med J 1986; 79:1238-41.
58. Liu C., Bayer A., Cosgrove S.E., et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 2011; 52:285-92.
59. Clerc O., Prod’hom G., Greub G., et al. Adult native septic arthritis: a review of 10 years of experience and lessons for empirical antibiotic therapy J Antimicrob Chemother 2011; 66:1168-73.
60. Mathews C. J., Kingsley G., Field M., et al. Management of septic arthritis: a systematic review. Ann Rheum Dis 2007; 66:440-5.
61. Sharff Katie A., Richards Eric P., Townes John M. Clinical management of septic arthritis. Curr Rheumatol Rep 2013; 15:332.
62. Senneville E., Legout L., Valette M., et al. Effectiveness and tolerability of prolonged linezolid treatment for chronic osteomyelitis: a retrospective study. Clin Ther 2006; 28:1155-63
63. Rao N., Hamilton C.W. Efficacy and safety of linezolid for Gram-positive orthopedic infections: a prospective case series. Diagn Microbiol Infect Dis 2007; 59:173-9.
64. Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom. J Antimicrob Chemother 2009; 63:849-61.
65. Jahoda D., Nyc O., Pokorný D., et al. Linezolid in the treatment of antibiotic-resistant gram-positive infections of the musculoskeletal system. Acta Chir Orthop Traumatol Cech 2006; 73:329-33.
66. French G. Safety and tolerability of linezolid. J Antimicrob Chemother 2003; 51(Suppl 2):ii45-53.
67. Woytowish M.R., Maynor L.M. Clinical relevance of linezolid-associated serotonin toxicity. Ann Pharmacother 2013; 47(3):388-97.
68. Moise P.A., Forrest A., Birmingham M.C., et al. The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, ОШ who have failed to respond to, vancomycin. J Antimicrob Chemother 2002; 50:1017-26.
69. Tsiodras S., Gold H.S., Sakoulas G., et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001; 358:207-8.
70. Rybak M.J., Hershberger E., Moldovan T., et al. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob Agents Chemother 2000; 44:1062-6.
71. Falagas M.E., Giannopoulou K.P., Ntziora F., Papagelopoulos P.J. Daptomycin for treatment of patients with bone and joint infections: a systematic review of the clinical evidence. Int J Antimicrob Agents 2007; 30(3):202-9.
72. Dailiana Z., Bindschedler M., Timerman A., et al. Daptomycin in the treatment of septic arthritis: high success rates in 6 years’ clinical experience of EU-COREˆSM. ESCMID, April 29, 2013.
73. Drew R.H., Perfect J.R., Srinath L., et al. Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of ОШ failing prior therapy. J Antimicrob Chemother 2000; 46:775-84.
74. Polenakovik H.M., Pleiman C.M. Ceftaroline for meticillin-resistant Staphylococcus aureus bacteraemia: case series and review of the literature. Int J Antimicrob Agents 2013; 42:450-5.
75. Yahav D., Lador A., Paul M., Leibovici L. Efficacy and safety of tigecycline: a systematic review and metaanalysis. J Antimicrob Chemother 2011; 66(9):1963-71.
76. Yin L.Y., Lazzarini L., Li F., et al. Comparative evaluation of tigecycline and vancomycin, with and without rifampicin, in the treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis in a rabbit model. J Antimicrob Chemother 2005; 55:995- 1002.
77. Twilla J.D., Gelfand M.S., Cleveland K.O., et al. Telavancin for the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis. J Antimicrob Chemother 2011; 66:2675-7.
78. CDC. Sexually Transmitted Diseases Treatment Guidelines 2014. Available from: http://www.cdc.gov/std/treatment/2014/2014-std-guidelines-peer-reviewers-08-20-2014.pdf
79. The 2012 European guideline on the diagnosis and treatment of gonorrhoea in adults recommends dual antimicrobial therapy. Eurosurveillance Edition 2012; Vol. 17/ Issue 47 Article 5.
80. Abraham S., Poehlmann C., Spornraft-Ragaller P. Gonorrhea: Data on antibiotic resistance and accompanying infections at the University Hospital Dresden over a 10-year time period. J Dtsch Dermatol Ges. 2013; 11(3):241-9.
81. 5th Report of the Mandatory Surveillance of Surgical Site Infection in Orthopaedic Surgery. http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1259151994683 (9 March 2010, date last accessed).
82. Cobo J., Miguel L.G., Euba G. et al. Early prosthetic joint infection: outcomes with debridement and implant retention followed by antibiotic therapy. Clin Microbiol Infect 2011; 17(11):1632-7.
83. Pensotti С., Nacinovich F., Guzzi L., et al. Stamboulian on behalf of the Bone and Joint Infection Working Group, FUNCEI Debridement and implant retention (DAIR) in prosthetic joint infection (PJI): experience of a bone and joint infection working group in Argentina. Available at: https://www.escmid.org/escmid.eP821.
84. Morata L., Senneville E., Bernard L., et al. A retrospective review of the clinical experience of linezolid with ОШ without rifampicin in prosthetic joint infections treated with debridement and implant retention. Infect Dis Ther 2014.
85. Peel T.N., Buising K.L., Dowsey M.M., et al. Outcome of debridement and retention in prosthetic joint infections by methicillin-resistant staphylococci, with special reference to rifampin and fusidic acid combination therapy. Antimicrob Agents Chemother 2013; 57:350-5.
86. San Juan R., Garcia-Reyne A., Caba P., et al. Safety and efficacy of moxifloxacin monotherapy for treatment of orthopedic implant-related staphylococcal infections. Antimicrob Agents Chemother 2010; 54:5161-6.
87. Gerald L., Mandell J.E.B., Raphael D. Principles and Practice of Infectious Diseases. 7th ed. Philadelphia, PA: Churchill, Livingstone, Elsevier; 2010.
88. Uçkay I., Tovmirzaeva L., Garbino J., et al. Short parenteral antibiotic treatment for adult septic arthritis after successful drainage. Int J Infect Dis 2013; 17(3):e199-205.
89. Wysenbeek A.J., Volchek J., Amit M., et al. Treatment of staphylococcal septic arthritis in rabbits by systemic antibiotics and intra-articular corticosteroids. Ann Rheum Dis 1998; 57:687-90.
90. Lane S., Merry P. Intra-articular corticosteroids in septic arthritis: beneficial ОШ barmy? Ann Rheum Dis Mar 2000; 59(3):240.
91. Ridgeway S., Wilson J., Charlet A., et al. Infection of the surgical site after arthroplasty of the hip. J Bone Joint Surg Br 2005; 87:844-50.
92. Mahomed N.N., Barrett J., Katz J.N., et al. Epidemiology of total knee replacement in the United States Medicare population. J Bone Joint Surg Am 2005; 87:1222-8.
93. Forse R.A., Karam B., MacLean L.D., Christou N.V. Antibiotic prophylaxis for surgery in morbidly obese patients. Surgery 1989; 106:750-7.
94. Prokuski L., Clyburn T.A., Evans R.P., Moucha C.S. Prophylactic antibiotics in orthopaedic surgery. Instr Course Lect 2011; 60:545-55.
95. Krijnen P., Kaandorp C.J.E., Steyerberg E. W., et al. Antibiotic prophylaxis for haematogenous bacterial arthritis in patients with joint disease: a cost eVectiveness analysis Ann Rheum Dis 2001; 60:359-366.
96. American Dental Association; American Academy of Orthopedic Surgeons. Antibiotic prophylaxis for dental patients with total joint replacements. J Am Dent Assoc 2003; 134:895-8.
97. American Academy of Orthopedic Surgeons. Information statement: antibiotic prophylaxis for bacteremia in patients with joint replacements. Available at: http://www.aaos.org/about/papers/advistmt/1033.asp
98. Seymour R.A., Whitworth J.M., Martin M. Antibiotic prophylaxis for patients with joint prostheses: still a dilemma for dental practitioners. Br Dent J 2003; 194:649-53.
99. Rossi M., Zimmerli W., Furrer H., et al. Antibiotic prophylaxis for late blood-borne infections of joint prostheses. (Article in German and French). Schweiz Monatsschr Zahnmed 2005; 115:571-9.
100. Mazzara T. Antibiotic Prophylaxis for Patients with Total Joint Replacements. Available at: http://www.orthoontheweb.com/pdfs/Total_Joint_Replacement_Antibiotic_Prophylaxis.pdf

Просмотров

0 Аннотация

0 PDF

0 Цитирования

Септический артрит у взрослых

Аннотация

Просмотров

Поделились

Процитировали Crossref